BC3 Technologies raises $200K pre-seed from TEDCO for bleeding-control tech
What's the deal? BC3 TechnologiesDealroom has a profile for this one. Try Dealroom →, a Baltimore-based, minority-owned medical technology company, has raised $200,000 in a pre-seed round led by TEDCODealroom has a profile for this one. Try Dealroom →. The Maryland Technology Development Corporation made the investment through its Pre-Seed Builder Fund.
What's the endgame? BC3 develops emergency preparedness and hemorrhage control technologies meant to help save lives before professional medical care arrives. Its flagship product, SEAL Hemostatic Wound Spray, is an FDA-cleared aerosolised spray designed to control severe external bleeding for both trained professionals and everyday citizens.
Where the money goes: The company plans to continue growth, enhance research and product development, and expand access to its technology for first responders, workplaces, families, the military, and communities. "We saw an opportunity to develop technology that helps bridge the gap between injury and professional medical care," said chief executive officer Wayne Grube, Jr.
Why now? More than 200,000 Americans die from trauma-related injuries each year, Grube said, underscoring demand for tools that address bleeding at the point of injury.
What's the Builder Fund? Sitting under TEDCO's Social Impact Funds, it targets technology and life sciences entrepreneurs who are traditionally overlooked. Beyond capital, it pairs founders with mentorship, operational guidance, and TEDCO's statewide network to prepare them for future investment.
Why the investor cares: "The innovative solution BC3 Technologies is offering has the potential to help people across the world—both civilian and military," said Jean-Luc Park, deputy chief investment officer and senior director of Social Impact Funds.
The signal: The deal reflects Maryland's push to grow its life sciences base, an industry TEDCO says generates $18.6 billion in economic activity and ranks the state's biopharma cluster third in the nation. Small, mission-driven cheques like this one show how public-backed funds are seeding early medtech founders who might otherwise struggle to attract capital.
Read more: citybiz
Image credit: Taylor Burnes
